Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,893,449
  • Shares Outstanding, K 268,112
  • Annual Sales, $ 2,169 M
  • Annual Income, $ 521,270 K
  • EBIT $ 800 M
  • EBITDA $ 829 M
  • 60-Month Beta 0.40
  • Price/Sales 5.49
  • Price/Cash Flow 23.04
  • Price/Book 5.51

Options Overview Details

View History
  • Implied Volatility 39.11% (-0.44%)
  • Historical Volatility 31.76%
  • IV Percentile 59%
  • IV Rank 34.77%
  • IV High 71.05% on 10/17/25
  • IV Low 22.08% on 02/12/25
  • Expected Move (DTE 11) 2.86 (6.59%)
  • Put/Call Vol Ratio 2.34
  • Today's Volume 254
  • Volume Avg (30-Day) 833
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 30,646
  • Open Int (30-Day) 68,857
  • Expected Range 40.46 to 46.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.65
  • Number of Estimates 8
  • High Estimate 0.79
  • Low Estimate 0.29
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +35.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.83 +7.71%
on 11/10/25
44.91 -4.48%
on 11/28/25
+2.09 (+5.12%)
since 11/07/25
3-Month
33.76 +27.09%
on 10/20/25
44.91 -4.48%
on 11/28/25
+5.21 (+13.82%)
since 09/08/25
52-Week
31.90 +34.48%
on 01/24/25
49.62 -13.54%
on 06/23/25
+7.08 (+19.77%)
since 12/06/24

Most Recent Stories

More News
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

- Event to Review R&D Progress and Outline Exelixis’ Strategy for Building Next-generation Oncology Franchises -

EXEL : 42.42 (-4.37%)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 432.37 (-5.62%)
EXEL : 42.42 (-4.37%)
GILD : 121.18 (-0.03%)
INSM : 199.55 (-2.18%)
UTHR : 476.56 (-2.61%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

– Presentations to be webcast on www.exelixis.com –

EXEL : 42.42 (-4.37%)
Exelixis: Q3 Earnings Snapshot

Exelixis: Q3 Earnings Snapshot

EXEL : 42.42 (-4.37%)
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted...

EXEL : 42.42 (-4.37%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised...

EXEL : 42.42 (-4.37%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised...

EXEL : 42.42 (-4.37%)
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 42.42 (-4.37%)
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat...

EXEL : 42.42 (-4.37%)
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

– CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neuroendocrine tumors (NET) – ...

EXEL : 42.42 (-4.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 45.42
2nd Resistance Point 45.01
1st Resistance Point 44.68
Last Price 42.42
1st Support Level 43.94
2nd Support Level 43.53
3rd Support Level 43.20

See More

52-Week High 49.62
Fibonacci 61.8% 42.85
Last Price 42.42
Fibonacci 50% 40.76
Fibonacci 38.2% 38.67
52-Week Low 31.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar